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Abstract: The diagnosis of osteoporosis is mainly based on clinical examination and bone mineral
density assessments. The present pilot study compares the plasma lipid and polar metabolite profiles
in blood plasma of 95 Singaporean-Chinese (SC) menopausal women with normal and low bone
mineral density (BMD) using an untargeted metabolomic approach. The primary finding of this study
was the association between lipids and femoral neck BMD in SC menopausal women. Twelve lipids
were identified to be associated with low BMD by the orthogonal partial least squares (OPLS) model.
Plasma concentrations of eight glycerophospholipid, glycerolipid, and sphingolipid species were
significantly lower in menopausal women with low BMD but higher in two glycerophospholipid
species (phosphatidylinositol and phosphatidic acid). Further, this study found no significant
differences in plasma amino acid metabolites. However, trends for lower 4-aminobutyric acid,
turanose, proline, aminopropionitrile, threonine, and methionine were found in women with low
BMD. This pilot study identified associations between lipid metabolism and femoral neck BMD in SC
women. Further studies are required on larger populations for evaluating the bone health effect of
these compounds and their usefulness as clinical biomarkers for osteoporosis prediction in women.
Keywords: metabolomics; lipidomics; osteoporosis; menopause; biomarkers
1. Introduction
Menopausal women have a greater risk of bone loss and developing osteoporosis. Osteoporosis
affects above 200 million people worldwide, and about 9 million osteoporotic fractures, of which
1.6 million are at the hip, are registered per year [1]. In Asian populations, hip fractures account for
around 30% of those worldwide, and in Singapore, hip fracture rates have increased by 1.2% annually
in Chinese women [2].
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In women, low oestrogen level is a risk factor for osteoporosis. Oestrogen withdrawal promotes the
activation of bone remodelling at the basic multicellular units (BMUs). Bone formation decreases because
there is reduction of osteoblastic cell lifespan, and bone resorption increases as a result of increased
differentiation and lifespan of osteoclasts [3]. The impact of oestrogen loss in bone metabolism, including
several biochemical and physiological alterations, is characterized by high levels of oxidative stress,
inflammation, and altered metabolism in the bone microenvironment [4,5]. Changes in lipid and polar
metabolites have been associated with oxidative stress and inflammation affecting bone metabolism.
Previous studies demonstrated that oxidative stress, caused by mitochondrial alterations, induces
reactive oxygen species (ROS) generation, and leads to osteoblast cell death by increasing the oxidized
bone microenvironment [6,7]. In addition, oestrogen withdrawal upregulates bone microenvironment
pro-inflammatory cytokines like interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α), granulocyte macrophage colony-stimulating factor, macrophage colony-stimulating factor
(M-CSF), and prostaglandin-E2 (PGE2), which regulate osteoclast differentiation and function and
therefore bone loss [8,9]. Osteoporosis may be present before diagnosis; despite current serum
biochemical analysis and radiological examination methods for screening of osteoporosis and fracture
risk in women [10], none of these methods are suitable for prediction of early bone loss in women.
The elucidation of the cellular and biochemical events on bone metabolism after oestrogen withdrawal
may lead to a better understanding of the molecular mechanisms involved in osteoporosis and bone
cell signalling pathways in women, and subsequently identify early predictors of bone loss that can be
used as prognostic markers.
Metabolomics offers the potential for analyzing the biochemical changes in the pathology of
diseases. Metabolomic studies are conducted by using several analytical platforms; however, nuclear
magnetic resonance (NMR) and mass spectrometry (MS) are the most widely reported techniques [11].
A small number of plasma metabolomic studies have reported that the metabolite concentration shifts
under menopausal conditions in ovariectomized (OVX) animals and humans [12–15], while numerous
studies on the relationship between bone loss and low oestrogen levels in both OVX animals and
humans have been reported [16–22].
Because of the limited information reported on the association between the plasma metabolome
and bone mineral density (BMD) in Singaporean-Chinese menopausal women (SC), research in this area
is required to allow the identification of potential metabolites that can be used to understand the causal
pathways involved in menopausal osteoporosis. We hypothesized that novel metabolomic markers will
improve the prediction of SC menopausal women at increased osteoporotic risk. Therefore, this study
aimed to analyze the lipid and polar metabolite profiles of blood plasma SC menopausal women using
a liquid chromatography–mass spectrometry (LC–MS) untargeted metabolomic approach. Moreover,
to maximize the identification of biomarkers associated with bone loss in menopausal women, we
also performed statistical tests on a restricted subset of the SC women with either osteoporosis
(T-score < −2.5) or normal BMD (T-score > −1). We hypothesized that lipids and polar metabolites
of women with osteoporosis differed from the whole population. Further, correlation analyses were
conducted between metabolites and femoral neck bone mineral density (BMD) in menopausal women.
2. Materials and Methods
2.1. Standards and Reagents
Formic acid, d2-tyrosine, sucrose, alanine, arginine, asparagine, aspartic acid, glutamic acid,
glutamine, histidine, homoserine, isoleucine, leucine, lysine, phenylalanine, proline, serine, theanine,
threonine, tyrosine, valine, amino acid standard mixture (physiological mixture), 16:0 d31-18:1 PE
(phosphatidylethanolamine), and ammonium formate were purchased from Sigma–Aldrich Chemicals
Co. (St. Louis, MO, USA). Ultrapure water was obtained from a Milli-Q® system (Millipore, Bedford,
MA, USA). Acetonitrile (ACN), methanol and isopropanol were optima LC–MS grade, chloroform
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was high-performance liquid chromatography (HPLC) grade, and all were purchased from Thermo
Fisher Scientific (Auckland, New Zealand).
2.2. Study Population, Inclusion and Exclusion Criteria
All subjects were informed about the objective of the study and gave their informed consent for
the participation in the present study. The study was approved by the Ethics Committee for Research
Involving Human Subjects, Singapore (Approval No. 2014/01066). The study was done in accordance
with the Declaration of Helsinki (2000) of the World Medical Association.
Ninety-seven SC menopausal women aged between 55 and 70 years were included in the study.
The key inclusion criterion was women who were at least five years menopausal (based on a history
of cessation of menstruation). Exclusion criteria included prior diagnosis with osteoporosis, diabetes
mellitus or any condition that affects bone and liver function, and to not be taking any medication that
will affect the study.
2.3. Blood Collection
Blood samples were taken only once between 8 and 10 a.m., after an overnight fast (10–12 h).
Blood was collected in ethylenediamine tetraacetic acid (EDTA) tubes (BD VacutainerTM K3E 15%,
Becton, Dickinson and Company, Plymouth, UK) and plasma samples transferred into separate 1 mL
tubes for extractions for metabolomics analysis; C-terminal telopeptide of type I collagen (CTx-1),
parathyroid hormone (PTH) and 25(OH) vitamin D3 were stored frozen at −80 ◦C and thawed on the
day of the analysis.
2.4. Analysis of Blood Parameters
Blood samples were taken to measure plasma markers of CTx-1 as well as PTH and 25(OH)
vitamin D3. CTx-1 and PTH concentrations were analyzed by electrochemiluminescence immunoassay
using the Roche COBAS® e411 system (Roche Diagnostics, Indianapolis, IN, USA). Serum 25(OH)
vitamin D3 concentration was analyzed using isotope-dilution liquid chromatography–tandem mass
spectrometry (IDLC–MS–MS) [23] by Canterbury Health Laboratories, Christchurch, New Zealand.
2.5. Bone Mineral Density
BMD was measured using dual X-ray absorptiometry (DXA). DXA scans of hip (femoral neck)
were carried out using a Hologic QDR-Discovery A densitometer (Hologic Discovery QDR 4500A
densitometer, Hologic Inc., Bedford, MA, USA). BMD was determined and women were classified
into normal or low BMD according to the World Health Organization (WHO) classification. WHO
provides an operational definition of osteoporosis based on T-score, where the T-score is the number
of the standard deviation below of the mean peak BMD for young-adults. Women with a BMD 2.5
standard deviations below are classified as osteoporotic. In this study, participants in the entire cohort
were classified into two groups according to bone status: (1) low BMD = women with a T-score < −1,
and (2) normal BMD = women with a T-score > −1.0. Further, a selected subset of participants were
also classified into two groups: (1) osteoporosis = women with a T-score < −2.5, and (2) normal BMD:
women with T-score > −0.1 [24].
2.6. Metabolomic Analysis
2.6.1. Sample Preparation
Lipids and polar metabolites were extracted from plasma using a biphasic solvent. Lipids were
analyzed by reverse-phase liquid chromatography–mass spectrometry (RP LC–MS) with positive- and
negative-mode electrospray ionization. Polar metabolites were analyzed by hydrophilic interaction
liquid chromatography–mass spectrometry (HILIC LC–MS) with only positive-mode electrospray
ionization. Briefly, plasma samples were thawed in fridge at 4 ◦C. Then, the samples were vortexed
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for 1 min. 100 µL of plasma was transferred to a microcentrifuge tube and 800 µL of cold
chloroform:methanol (1:1 v/v) were added to the tubes. The tubes were agitated by hand for 1 min
and the samples were stored for 30 min at -20 ◦C. 400 µL of water were added to each sample and
vortexed for 30 s. The samples were centrifuged for 15 min at 13,913 g at 4 ◦C. 200 µL of the lower
phase (organic phase) were taken for lipid analysis and transferred to a new microcentrifuge tube to
evaporate to dryness under a stream of nitrogen. Two hundred and fifty µL of the upper phase (polar
aqueous) were collected for polar metabolite analysis and transferred in to new microcentrifuge tube
to evaporate to dryness under stream of nitrogen. The lower-phase tubes were reconstituted in 100 µL
of Folch solvent mixture (choroform:methanol 2:1 v/v) containing 16:0 d31-18:1-PE internal standard at
10 µg/mL concentration. The upper-phase tubes were reconstituted in 300 µL of ACN:water (1:1 v/v)
containing formic acid (0.1%). All the samples were vortexed for 1 min, centrifuged for 10 min 13,913 g
at 4 ◦C and 100 µL were transferred to a vial containing an insert and stored at 4 ◦C for immediate
polar metabolite analysis. Polar metabolite quality control (QC) samples were prepared with 60 µL of
each sample and placed in a tube to be pooled. The pooled QC samples were transferred into multiple
pooled QC vials. Lipid QC samples were prepared with 20 µL of each sample. The pooled lipid QC
samples were aliquoted into multiple pooled quality control vials [25].
2.6.2. LC-MS Conditions and Metabolite Identification
Untargeted metabolomic approach was carried out on the Thermo LC–MS system (Thermo
Fisher Scientific, Waltham, MA, USA). This system consisted of an Accela 1250 quaternary pump,
a Thermo-PAL auto-sampler fitted with a 15,000 psi injection valve (CTC Analytics AG., Zwingen,
Switzerland).
Lipid chromatographic separation was conducted by using a C18 column (100 × 2.1 mm; 1.7 µm
particle size, Waters, Milford, MA, USA). The samples were separated with a gradient elution program
and flow rate of 600 µL/min. The mobile phase was a mixture of 0.1% formic acid in ACN–isopropanol
(50:50, v/v) (Solvent A), 0.1% formic acid in ACN-water (60:40 v/v) with 10 mM ammonium formate
(Solvent B) and a mixture of 0.1% formic acid in isopropanol-ACN (90:10 v/v) with 10 mM ammonium
formate (Solvent C). The gradient elution was conducted starting with 85% solvent B (0–1 min),
decreased at 70–18% (2–11 min) and held at 1% (11.50–14 min), returned to 85% (22–27 min), while
solvent A was held at 100% (14.1–22 min) and allowed to equilibrate for 5 min prior to the next sample
injection. Column effluent was connected to a 2 µL injection loop and a Q Exactive Orbitrap mass
spectrometer using positive and negative electrospray ionization. Data were collected in profile data
acquisition mode over a mass range of m/z 200–2000 at a mass resolution setting of 70,000 with a
maximum trap fill time of 100 ms using the Xcalibur software package ver. 2.2 SP1.48 provided by the
manufacturer (Thermo Fisher Scientific, San Jose, CA, USA). Lipid positive ion mode parameters were
as follows: spray voltage, 3.2 kV; capillary temperature, 275 ◦C; capillary voltage, −0.2 V, tube lens
120 V. Negative ion mode parameters were as follows: spray voltage, −3.2 kV; capillary temperature,
275 ◦C; capillary voltage, −0.1 V, tube lens −100 V.
Polar metabolites chromatographic separation was conducted by using a ZIC-pHILIC column
(100 mm × 2.1 mm, 5 µm; Merck, Darmstadt, Germany). The samples were separated with a gradient
elution program and a flow rate of 250 µL/min. The mobile phase was a mixture of ACN-formic acid
(99.9:0.1, v/v) (solvent A) and water–ammonium formate (16 mM, pH 6.3) (solvent B). The gradient
elution programme was: held at 97% A (0–1 min), 97–70% A (1–12 min), 70–10% A (12–14.5 min),
held at 10% A (14.5–17 min), returned to 97% A (17–18.5 min) and allowed to equilibrate for a further
5.5 min prior to the next injection. Column effluent was connected to a 20 µL injection loop and an
Exactive Orbitrap mass spectrometer using positive and negative electrospray ionization. Data were
collected in profile data acquisition mode over a mass range of m/z 55–1100 at a mass resolution setting
of 25,000 with a maximum trap fill time of 100 ms using the Xcalibur software package provided by
the manufacturer. Samples were run in positive ionization mode. HILIC positive ion mode parameters
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were as follows: spray voltage, 2.7 kV; capillary temperature, 275 ◦C; capillary voltage, 29.1 V, tube
lens 108.8 V.
2.6.3. Metabolite Identification and Processing
Raw LC–MS data were acquired using Xcalibur v2.1 software (Thermo Scientific, Hemel
Hemstead, UK). The raw data for each sample analysis consisted LC-MS signals identified by m/z,
retention time and ion signal intensity. The full datasets were imported and converted to .mzXML files
by MSconvert (ProteoWizard; Software Foundation, San Diego, CA, USA). Then, XCMS was used to
extract the ions of the spectra (determines mass-to charge ratios m/z), detect chromatographic peaks
(retention time), assign them to molecular ions or adducts, align peaks across samples and quantify
their relative abundance, which is calculated based on peak area ratios from sample peaks. Finally,
peak detection, grouping, and retention time correction were recorded into peak tables [26]. Data from
lipids and polar metabolites were unavailable for two participants. In total, the full datasets for 95
participants were included in the analysis.
Peak intensities of each sample were corrected for run-order signal correction by using a locally
quadratic (loess) regression model to fit the QC values. Metabolites with a coefficient of variation of
their QC values superior to 30% after run-order correction were removed from the peak table [27].
Missing values in the peak tables were replaced by using k-nearest neighbour (KNN) method. Tentative
identification of key metabolites was achieved by using an in-house library, as well as in the appropriate
metabolite databases: LipidSearch software (Thermo Scientific, San Jose, CA, USA), the Human
Metabolome data-base (HMDB) [28] and METLIN [29].
2.7. Statistical Analyses
2.7.1. Univariate Analysis
The characteristic of the study population was compared using t-test. Normality of the data
was tested using the Shapiro–Wilk normality test in. Age, BMI, CTx-1, PTH, vitamin D3, and
BMD parameters were expressed as mean and standard deviation (SD). Analysis of covariance
was performed to adjust for possible confounders using age and BMI. In addition, our objective
was to assess whether lipids and amino acids were associated to BMD. Age-adjusted correlation
coefficients were calculated for each lipid and polar metabolites. Age and BMI adjusted mean
concentrations of each lipid and polar metabolite were calculated in both groups. To assess whether
those associations were independent, we evaluated the pairwise correlations between identified lipids
and polar metabolites. p values were calculated using Benjamini–Hochberg false discovery rate (FDR),
where FDR p-value < 0.05 was considered as statistically significant. The fold changes in lipids and
polar metabolites between BMD groups were performed by parametric test using Metaboanalyst 4.0
web server [30]. Statistical data analysis was performed using R (R 3.3.3, R Foundation for Statistical
Computing, Vienna, Austria).
2.7.2. Multivariate Analysis
Prior to multivariate analysis (MVA), different data sets were created (1) an entire cohort
containing all samples (n = 95) and (2) a subset (n = 30), in which only 15 women with osteoporosis and
15 women with normal BMD were included. Both the entire cohort and subset were used for modelling
the correlations between BMD and metabolites in SC menopausal women. For MVA, each variable was
mean centered and univariate scaled over all the samples and imported to SIMCA-P+ v14.1 software
(Umetrics, Umea, Sweden). SIMCA was used to construct an orthogonal partial least squares (OPLS)
regression model for analyzing BMD. The supervised method analyzes the linear relationship between
BMD and metabolite profiles. In OPLS, the R2X, R2Y, and Q2 (cum) parameters were used for the
model evaluation, representing the explanation, fitness and prediction power respectively. R2X is
the percentage of all LC-MS response variables explained by the model. R2Y is the percentage of all
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sample variables explained by the model. Q2 is the percentage of all sample variables predicted by
the model [31]. Only one component was extracted to predict membership probability in each group.
Then, from the coefficient score plot, a normal probability plot was created and 95% of features were
excluded to fit a new model. The objective was to select the most relevant variables from the interaction
between the metabolites and femoral neck BMD relative to bone status (step 1, OPLS methods) and to
add these variables into a new model to display the contribution of each metabolite to the modulation
of osteoporosis (step 2).
3. Results
This study analyzed lipid and polar metabolites in blood plasma of SC menopausal women.
Overall, after analyzing lipid and polar metabolites, two data sets were created for further multivariate
analysis. The correlations between those compounds and femoral neck BMD were investigated by
using univariate and OPLS regression statistical analyses. The lipid profiles revealed differences in
plasma of women with normal BMD and lower BMD/ osteoporosis. Polar metabolites exhibited no
differences; however, a trend was observed in several metabolites such as a peptide, amino acids,
and amines.
3.1. Characteristics of the Menopausal Women Bone Status
Women with low BMD were older and had lower BMI when compared with women in the
normal group. PTH concentrations were lower in the menopausal groups with low BMD/osteoporosis
compared to normal BMD groups. (Table 1). Serum 25(OH) vitamin D3 concentrations were adequate
(equal to or >50 nmol/L) for all the groups. Bone resorption marker (CTx-1) concentrations were
significant higher in the menopausal group with low BMD/ osteoporosis compared to normal
BMD groups.
Table 1. Characteristics of the SC menopausal women according to bone status, entire cohort (n = 95)
and subset (n = 30) analyses.
Parameters








(n = 15) p-Value
Age (years) 59.4 (4.19) 61.3 (4.19) 0.06 58 (3.42) 61 (3.42) 0.02 *
BMI (kg/m2) 23.8 (2.61) 22.5 (2.61) 0.04 * 23.8 (2.25) 20.7 (2.25) <0.001 *
PTH (pmol/L) 4.7 (1.35) 4.5 (1.32) 0.29 4.8 (1.59) 4.3 (1.59) 0.08
CTx-1 (ug/L) 0.44 (0.21) 0.55 (0.20) 0.02 * 0.41 (0.26) 0.64 (0.26) 0.04 *
Vitamin D (nmol/L) 57.4 (15.24) 60.1 (14.87) 0.23 56.5 (16.84) 54.8 (16.84) 0.81
Femoral neck BMD (g/cm2) 0.75 (0.05) 0.60 (0.05) <0.001 * 0.78 (0.04) 0.51 (0.04) <0.001 *
Data are presented as mean (SD). The resulting p-values obtained by ANOVA are given. * p < 0.05 was considered
as statistically significant.
3.1.1. Entire Cohort
Table 1 shows the population characteristics for the menopausal women. The mean ages for these
groups were 59.4 and 61.3 for the normal and low BMD groups, respectively. Women with low BMD
had lower BMI than those with normal BMD (23.8 vs. 22.5 kg/m2, p = 0.04) There were no significant
differences between the groups for PTH and 25(OH) vitamin D3 concentrations. Mean PTH was 4.7
and 4.5 pmol/L (p = 0.29) and mean 25(OH) vitamin D3 concentrations were 57.4 and 60.1 nmol/L
(p = 0.23) for the normal and low BMD groups, respectively. However, CTx-1 concentrations and
femoral neck BMD were significant different. Mean CTx-1 concentrations were 0.44 and 0.55 ug/L for
the normal versus low BMD group. Femoral neck BMD was 0.75 g/cm2 and 0.60 g/cm2 (p ≤ 0.001) for
the normal and low BMD groups, respectively.
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3.1.2. Subset
Women with osteoporosis were older than those with normal BMD (58 vs. 61, p = 0.02), and had
lower BMI (23.8 vs. 20.7 kg/m2, p = 0.008). Similarly, there were no significant differences between the
groups for PTH, CTx-1, and 25(OH) vitamin D3 concentrations. Mean PTH was 4.8 and 4.3 pmol/L
(p = 0.08) and mean 25(OH) vitamin D3 concentrations were 56.1 and 54.8 nmol/L (p = 0.81) for the
normal BMD and osteoporosis groups, respectively. Serum CTx-1 concentrations were 0.41 and
0.64 ug/L (p = 0.04) and femoral neck BMD was 0.78 g/cm2 and 0.51 g/cm2 (p < 0.001) for the normal
BMD and osteoporosis groups, respectively.
3.2. Untargeted Analysis Metabolomic Approach
3.2.1. Lipids
Entire Cohort
Overall, 7082 features (positive and negative ionization) were detected by lipidomics and after
filtration and removal of noise and unstable compounds, the remaining 1662 lipid features were fitted
within the OPLS model. The OPLS model was fitted and the cumulative R2Y and Q2 values were 0.302
and 0.042, respectively (Table 2). However, the predictive ability for the model Q2 was low, which
indicated that it was not a good model. Therefore, the OPLS model with 1662 features was not able to
explain the association of the explanatory variables and femoral neck BMD.
Subsequently, a new model was created by selecting those features based on the exclusion
of un-correlated lipid features on the normal probability coefficient score plot (between >0.05 and
<0.95%), from model 1 resulting in 98 lipids being selected. The new model yielded R2Y and Q2
values of 0.469 and 0.233, respectively (Table 2). The new OPLS model parameters for fitness and the
predictive capability Q2 were better than in the previous model (step 1) and significant based on the
cross-validated analysis of variance (CV-ANOVA) (p ≤ 0.001). Figure 1a shows the OPLS predictive
model for femoral neck BMD of the lipidomic plasma extracts from normal and low BMD menopausal
women. A lineal clustering of the low BMD menopausal women occurred on the left hand of the plot,
while normal BMD were clustered on the right top hand side. The results indicated that lipids change
linearly with femoral neck BMD (R2Y = 0.469). Further, positive correlations values (upper portion of
the plot) indicated increased serum lipid concentrations in normal BMD versus low BMD.
Table 2. Parameters of orthogonal partial least-squares regression models based on the data from lipids
separation for the entire cohort and the selected subset of SC menopausal women.
Dataset Step Component R2X R2Y Q2
Entire cohort (n = 95) 1 1P and O1 0.395 0.302 0.042
Entire cohort (n = 95) 2 1P and O2 0.678 0.469 0.233
Subset (n = 30) 1 1P and O1 0.434 0.601 0.209
Subset (n = 30) 2 1P and O1 0.540 0.773 0.540
P predictive. O orthogonal in X. Component: number of significant component calculated by cross validation. R2X
value is the predictive and orthogonal variation in model samples (X) explained by the model. R2Y value is the
amount of variation in X which is correlated to Y (response matrix). Q2 value describes the predictive ability of
the model.
We found negative associations between femoral neck BMD and the lipids of menopausal
women. Based on univariate analysis, the top 50 features were significant by t-tests. However,
only 5 features resulted to be known lipids and these were associated to femoral neck BMD
(Table 3). The 5 known lipids include 3 phosphatidylserine (PS), 1 diacylglycerol (DG) and 1
plasmenylphosphatidylethanolamine (plasmenyl-PE). The PS species detected comprised 36:1, 33:6
and 29:6, where a decreasing common trend was observed in low BMD group. A correlation matrix
revealed negative correlations among the five lipids and femoral neck BMD, PS 36:1 (r = −0.027),
PS 33:6 (−0.070), PS 29:6(−0.086), DG 42:4 (r = −0.075), and plasmenyl-PE 38:4 (r = −0.01).
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0.921
(0.714–1.188) 0.967 −0.296 −0.086
DG 42:4; [M + NH4]+ 0.850(0.395–1.828)
0.947
(0.725–1.219) 0.804 −0.176 −0.075
Plasmenyl-PE 38:4; [M + H]+ 0.745(0.353–1.571)
0.841
(0.653–1.083) 0.760 −0.174 −0.01
Lipids are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare lipid mean
concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient. Statistical p-value calculated
using Benjamini–Hochberg false discovery rate (FDR). p-value < 0.05 was considered as statistically significant. Fold
of change (FC) expressed as the relation betwee the lipid mean of the normal BMD group to the lipid mean of the
low BMD group. + Adducts in positive ionisation. – Adducts in negative ionisation. PS (phosphatidylserine), DG
(diacylglycerol), plasmenyl-PE (plasmenylphosphatidylethanolamines).
Subset
Similarly, an additional OPLS regr sion model was fitted to the subset of samples (n = 30) with
the 1662 lipids to analyze the relationship of femoral neck BMD and lipids.
This OPLS model showed the relationship between the predictive values equals to the observed
responses and this was described by high values of R2Y and Q2, 0.601 and 0.209 (Table 2). After
excluding 95% of the lipids, a new OPLS model (step 2) was fitted with 149 lipids. The scatter plot for
this statistical analysis showed a straight line indicating a relationship between the predictive values
equal to the observed responses (Figure 1b). This new model showed higher values of R2Y and Q2
0.773 and 0.54 and was significant based on the CV-ANOVA (p ≤ 0.001), and also showed a strong
linear correlation of R2Y = 0.772. Lipids that were highly associated to the normal and osteoporosis
groups through both approaches are listed in Table 4. Twelve known lipids were significant and
included 1 phosphatidic acid (PA), 2 ceramide-1phosphates (CerP), 4 phosphatidylserine (PS) species,
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3 diacylglycerol (DG) species, 1 phosphatidylethanolamine (PE), and 1 phosphatidylinositol (PI)
(Table 4). A correlation matrix revealed negative correlations among eight lipids and femoral neck
BMD, while a positive correlation was observed with PS (20:4), PI, CerP (24:0), and PE (Table 4).
Table 4. Means and 95% confidence intervals of lipids associated to the subset of selected






(n = 15) p-Value log2 (FC) Correlation
b
PA 34:4; [M − H]− 0.531(0.321–0.878)
1.617
(0.822–3.182) 0.005 * 0.412 −0.403
CerP 38:1; [M + H]+ 1.871(1.196–2.927)
0.605
(0.3319–1.105) 0.002 * −0.637 −0.384
PS 20:4; [M − H]− 0.547(0.330–0.906)
1.585
(0.804–3.124) 0.008 * 0.395 0.274
DG 40:0; [M + NH4]+ 1.545(0.907–2.630)
0.425
(0.207–0.870) 0.0029 * 0.729 −0.270
PS 33:6; [M + H]+ 1.435(0.908–2.267)
0.504
(0.277–0.933) 0.0046 * −0.560 −0.363
PS 31:6; [M + H]+ 1.423(0.886–2.286)
0.506
(0.267–0.958) 0.0065 * −0.656 −0.377
PS 32:6; [M + H]+ 1.414(0.885–2.259)
0.515
(0.274–0.967) 0.007 * −0.573 −0.359
PI 14:0; [M − H]− 0.608(0.357–1.036)
1.572
(0.767–3.220) 0.022 * 0.327 0.165
DG 42:4; [M + NH4]+ 1.510(0.976–2.336)
0.574
(0.319–1.033) 0.005 * −0.327 −0.374
CerP 24:0; [M − H]− 1.254(0.728–2.160)
0.418
(0.201–0.869) 0.010 * −0.265 0.008
DG 47:5; [M + NH4]+ 1.670(0.920–3.032)
0.854
(0.382–1.905) 0.135 −0.351 −0.014
PE 42:1; [M − H]− 0.592(0.346–1.013)
1.246
(0.605–2.568) 0.069 0.585 0.034
Lipids are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare lipid mean
concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient; Statistical p-value calculated using
Benjamini–Hochberg false discovery rate (FDR). * p-value < 0.05 was considered as statistically significant. Fold of
change (FC) expressed as the relation between the lipid mean of the normal BMD group to the lipid mean of the
osteoporosis group. + Adducts in positive ionisation. − Adducts in negative ionisation. PS (phosphatidylserine),
PA (phosphatidic acid), DG (diacylglycerol), PE (phosphatidylethanolamine), CerP (ceramide-1-phosphate), PE
(phosphatidylethanolamine), and PI (phosphatidylinositol).
3.2.2. Polar Metabolites
Entire Cohort
574 features (positive ionisation) were detected by metabolomics. After filtration and removal of
unwanted background and unstable compounds, the remaining 127 polar metabolites were fitted in an
OPLS regression model. However, cumulative R2Y and Q2 values were 0.223 and −0.371, respectively
(Table 5), and the predictive ability for the model Q2 was very low, which indicated that it was not a
suitable model.
Features scoring between >0.05 and <0.95% on the normal probability coefficient score plot were
taken out to fit a new model (step 2), which had only 12 polar metabolites. Values of cumulative R2Y
and Q2 values of for this OPLS model were 0.205 and 0.035, respectively (Figure 2a). Both step 1 and
step 2 for polar metabolites showed little prediction for the two OPLS regression models. Therefore, the
OPLS model with 127 features was not able to explain the association of the explanatory variables and
femoral neck BMD. However, this analysis provided evidence for the association between four polar
metabolites and femoral neck BMD (Table 6), 4 aminobutyric acid (r = −0.013), threonine (r = −0.172),
a tripeptide formed by asparagine-glycine-cystine (asn-gly-cys) (r = −0.059), and turanose (r = −0.039).
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Table 5. Parameters of orthogonal partial least squares regression models based on the data from polar
metabolites separation for the entire cohort and the selected subset of SC menopausal women.
Dataset Step Component R2X R2Y Q2
Entire cohort (n = 95) 1 1P and O1 0.483 0.223 −0.371
Entire cohort (n = 95) 2 1P and O1 0.512 0.205 0.035
Subset (n = 30) 1 1P and O1 0.437 0.749 −0.399
Subset (n = 30) 2 1P and O1 0.514 0.526 0.247
P: predictive. O: orthogonal in X. Component: number of significant component calculated by cross-validation. R2X
value is the predictive and orthogonal variation in model samples (X) explained by the model. R2Y value is the
amount of variation in X which is correlated to Y (response matrix). Q2 value describes the predictive ability of
the model.
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Figure 2. Orthogonal partial least squares (OPLS) scatter plot of polar metabolites, showing relationship
between polar metabolites and femoral neck BMD in SC menopausal women with normal (green circles)
and low BMD and osteoporosis (red circles) values based on orthogonally filtered partial square (OPLS)
regression model 2 with 12 polar metabolites among 95 women, entire cohort (a) and 30 women,
subset (b). t[1]/u[1] correlation plot; t1 refers to scores of the first component in independent variables;
u1 refers to scores of the first component in responses.
Table 6. Means and 95% confidence intervals of polar metabolites associated to the entire cohort
of SC menopausal women (n = 95) with normal and low femoral neck BMD in univariate and
multivariate approaches.








(0.679–1.125) 0.062 −0.185 −0.013
Threonine 1.315(0.806–2.011)
0.843
(0.658–1.081) 0.073 −0.159 −0.172
Asn–Gly–Cys 0.794(0.512–1.230)
1.014
(0.512–1.230) 0.337 0.058 0.059
Turanose 1.319(0.858–2.028)
0.845
(0.657–1.087) 0.076 −0.174 −0.039
Polar metabolites are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare polar
metabolites mean concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient. Statistical
p-value calculated using Benjamini–Hochberg false discovery rate (FDR). p-value < 0.05 was considered as
statistically significant. Fold change expressed as the relation between the metabolite mean of the normal BMD
group to the metabolite mean of the low BMD group.
Subset
In addition, the OPLS regression (step 1) was fitted to the subset of samples (n = 30) with the
127 polar metabolites to analyze the relationship of femoral neck BMD and polar metabolites but this
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model did not show prediction Q2 = −0.399 (Figure 2b). After filtering using coefficient selection
section (as described above) the OPLS model 2 showed a higher cross validation value Q2 = 0.247 when
compared with the model from step 1 (Table 5). The correlation matrix revealed negative correlations
among lipids and femoral neck BMD, proline (r = −0.295), aminopropionitrile (r = −0.315), threonine
(r = −0.170), and asn-gly-cys (r = −0.038); while positive correlation was observed with methionine
(r = −0.494) (Table 7).
Table 7. Means and 95% confidence intervals of polar metabolites associated to a subset of
selected SC menopausal women (n = 30) with normal BMD and osteoporosis in univariate and
multivariate approaches.








(0.384–1.609) 0.084 −0.234 −0.295
Aminopropionitrile 0.729(0.418–1.272)
1.848
(0.875–3.905) 0.03 * −0.270 −0.315
Threonine 1.561(0.911–2.674)
0.765
(0.371–1.579) 0.081 −0.219 −0.170
Methionine 1.534(0.894–2.632)
0.758
(0.366–1.567) 0.085 0.141 0.494
Asn-Gly-Cys 1.428(0.782–2.607)
0.593
(0.264–1.334) 0.056 0.142 −0.038
Polar metabolites are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare polar
metabolites mean concentrations. a Covariates: age and BMI; b Age-adjusted correlation. Statistical p-value
calculated using Benjamini–Hochberg false discovery rate (FDR). * p-value < 0.05 was considered as statistically
significant. Fold change expressed as the relation between the metabolite mean of the normal BMD group to the
metabolite mean of the osteoporosis group.
4. Discussion
The potential of metabolomics was explored for the discovery of molecules associated with
BMD loss in SC menopausal women. It is well established that bone loss is linked to age and low
levels of oestrogen in women in both Caucasian and Asian populations. After menopause, there are
several molecular changes affecting bone metabolism, where those alterations result in an increased
bone resorption and a declined BMD [32,33]. Thus, the identification of novel potential biomarkers
may be useful for understanding the connections of the lipids and polar metabolites associated with
osteoporosis and their capacity to predict bone loss in SC menopausal women.
In order to optimize the prediction of biomarkers for bone loss, we created a second data set
(subset) to analyze the relationship between the plasma metabolome of SC women with osteoporosis
(T-score < −2.5) and normal BMD (T score > −1). Therefore, in this study, we presented results from
univariate and multivariate analysis using two different datasets: the entire cohort and a selected
subset of samples. The findings were similar in both datasets; however, with the subset analysis, more
lipids were identified as being of significance. This statistical filtering using OPLS regression modelling
facilitated the removal of un-correlated lipid features and allowed several lipids to be detected as
predictors of menopausal osteoporosis in women.
4.1. Lipids
In this study, we compared changes of the lipid profiles in SC menopausal women
and the relationship of those lipids with femoral neck BMD. Glycerophospholipid species PS
(20:4/29:6/31:36/32:6/33:6), PE (42:1), PA (34:4), and PI (14:0) were found to be different between
normal BMD and osteoporosis groups.
Lipid metabolism disorders have been linked to pathological conditions including obesity,
metabolic syndrome, cardiovascular diseases, and bone loss, where cells and signaling pathways
may be affected [34]. Adipocytes and osteoblasts are derived from the mesenchymal stem cells (MSC)
and the balance of osteoblast versus adipocyte requires interactions between extracellular signaling
stimuli. Changes in any of those factors enhances fat bone deposition and promote bone loss [35].
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Oestrogens plays a key role on the cell fate of MSCs to differentiate into either osteoblasts or adipocytes;
oestrogen also regulates inflammation [36,37]. Further, peroxisome proliferator-activated receptor
(PPARy) transcription factor is essential for adipogenesis. Thus, altered lipid metabolism causes
oxidative stress and increased expression of PPARy, which reduces osteoblast number in the skeleton,
and oestrogren contributes to the regulation of this PPARy signaling pathway [38,39].
Oestrogen deficiency induces bone loss and changes in lipid profiles, BMD and cytokines; however,
little information exists on the application of plasma lipidomics for studying menopausal osteoporosis.
In vivo and in vitro studies have reported that lipid metabolism disorders promote bone loss by
inhibiting osteoblast differentiation and promoting adipogenic differentiation through MSCs stimuli.
Phosphatidylinositol (PI) metabolism is essential for signaling by receptor activator of nuclear factor κB
(RANK), a local regulator of osteoclastogenesis and bone resorption [40,41]. Our study showed elevated
concentrations of PI species (14:0) in SC women with low BMD/ osteoporosis compared with normal
BMD group, suggesting that PI species may lead to chronic inflammatory processes and this might
induce bone loss in menopausal osteoporosis. Circulating levels of several lipid classes also have been
associated with physiological processes including the regulation of inflammation. In an in vitro study,
lipid metabolism of PE, PS, and LysoPC changed during MSCs activation due to pro-inflammatory
stimuli with TNF-α and IFN-γ [42]. This suggests that changes in lipid profiles promote production of
cytokines and differentiation of osteoclasts and may be attributed to oestrogen withdrawal.
Diacylglycerols (DG) are cellular mediators released from membrane lipids that play a key role in
the regulation of inflammation and diseases [43]. Our study showed a decrease in the concentrations
of glycerolipid species identified as DG (40:0/42:4) in the osteoporosis group compared to the normal
BMD menopausal group. While it is not clear whether DG levels are associated with bone mass
there is evidence suggesting a relationship between circulating DG profiles and oestrogen loss.
A previous study reported plasma DG (33:2) decreased with ageing [44]. Additionally, an animal
study reported serum monoacylglycerol and triacylglycerol concentrations decreased in OVX rats
as a model of oestrogen deficiency [45], suggesting that lipid profiles and oestrogen loss upregulate
bone-proinflammatory cytokines, which control osteoclast differentiation and promote bone loss.
However, information on the association between plasma lipids and femoral neck BMD in
menopausal women is limited. Previous studies in menopausal women have reported conflicting
associations between triacylglycerol and hip BMD [34,46,47]. Our findings showed a positive
association between DG species and hip femoral neck BMD. This result indicates that lipid
profile changes may be involved in MSCs functional, anti-inflammatory activities and cytokine
production as a result of oestrogen withdrawal, which enhances MSC signaling and inhibits osteoblast
differentiation [48–50]. However, further studies are needed to clarify the links between plasma lipid
concentrations and femoral neck bone loss in menopausal women.
Sphingolipids also play a structural role in cellular membranes and act as bioactive signalling
molecules. Ceramide is one of the simple sphingolipids and is involved in the control of many
cellular processes including proliferation, differentiation, and apoptosis [51,52]. It has shown that
phosphorylated ceramide (ceramide 1-phosphate) stimulates cell survival and proliferation in bone
marrow-derived macrophages through molecules such as NF-κB, RANK, and its ligand RANKL [53,54].
However, in our study two sphingolipid species, CerP (24:0/38:1), were significantly reduced in the
osteoporosis group compared with the normal BMD group. Our results contradict a previous animal
study of oestrogen loss, where CerP concentrations were upregulated in OVX rats [45]. Furthermore,
in a human study, Lee et al. [55] found that higher sphingosine-1-phosphate (S1P) concentrations
were associated with low BMD in menopausal women. This suggests that the increased levels of
CerP promotes differentiation of bone marrow-derived macrophages with biological effects on bone
metabolism and could be attributed to oestrogen deficiency.
Taken together, our findings suggest that altered lipid metabolism could be a regulator of bone cell
differentiation and bone loss in SC menopausal women. Further studies are required to investigate the
potential role of these lipids as biomarkers for early diagnosis of bone loss in SC menopausal women.
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4.2. Polar Metabolites
This approach enabled the identification of amino acids, amines, and other polar metabolites.
Our study found no significant associations between polar metabolites and femoral neck BMD in SC
menopausal groups based on OPLS analysis. However, proline, threonine, and aminopropinitrile
concentrations were found to be lower in SC menopausal women with low BMD and osteoporosis
based on univariate analysis.
Amino acids play a key role in bone health and are involved in bone remodeling. During
osteoporosis, alterations in amino acids may affect bone mass, suggesting that lower levels of circulating
amino acids are associated with low BMD. Previous metabolomic studies in menopausal women have
reported tryptophan, lysine, homoserine, and 3-hydroxy-L-proline concentrations decreased in the
osteoporosis group compared with pre/menopausal women with normal BMD using GC-MS [56].
Miyamoto et al. [20] reported serum concentrations of a dipeptide formed with glycine and glycine
(Gly-Gly) and cysteine were lower and hydroxyproline concentrations were higher in low BMD
menopausal women using capillary electrophoresis/mass spectrometry (CE-MS). You et al. [22] found
higher glutamine concentrations and lower lactate and acetone concentrations associated with low
BMD in Taiwanese women using 1H NMR Spectroscopy.
Amino acids modulate bone marrow stem cell (BMSC) function, signalling, proliferation, and
differentiation in the bone marrow. Arginine is the precursor for the synthesis of many molecules including
urea, nitric oxide, proline, and glutamate [57]. Disorders in arginine metabolism are suggested to cause
decalcification, disturbance in calcium absorption, and osteomalcia. Growth hormone and insulin-like
growth factor-I, both bone-forming growth factors, are stimulated by arginine and a disorder in these
factors cause an increase in inflammatory cytokines and osteoporosis [58]. Proline and its metabolite
hydroxyproline are the major amino acids components in collagen, and serum hydroxyproline can
be used as bone collagen degradation marker [16,59]. Homocysteine is a metabolite in methionine
metabolism and at high levels it interferes with collagen cross-linking, suggesting that increased
homocysteine levels can lead to increased fracture risk in ageing [60]. Further, aminopropinitrile
has been reported in in vitro studies as a collagen cross-linking inhibitor and, with homocysteine,
caused decreased bone strength [61]. The mechanistic implications of altered metabolites and their
association to bone remodeling and the link to BMD are not clear, but both BMSC differentiation and
collagen formation are critical factors that influence BMD, suggesting that perturbations of amino acids
under menopausal osteoporosis may partly contribute to bone loss in elderly women. Information
on the association between polar metabolites and SC menopausal women is scarce and needs to be
corroborated with further work. As we were unable to test for a possible relationship between polar
metabolites and femoral neck BMD due to our small study groups and the high variability among
participants, our findings need to be kept in perspective.
The limitations of our study include the small number of participants and higher variability
among them such as genetic, age, environment, diet and lifestyle, and body composition. However,
this was addressed when we analyzed two different datasets, and both the entire cohort and subset
findings were consistent as the subset study showed similar compounds to those already detected in the
entire cohort. Supporting these findings is the fact the same compounds were associated with BMD in
both datasets’ analyses for the pathology of osteoporosis. Overall, future studies on larger populations
are needed to confirm these findings and enable more reliable results for assessing the association
between metabolome and femoral neck BMD for prognosis of osteoporosis in SC menopausal women.
5. Conclusions
This pilot study suggested that plasma lipids and polar metabolites differed between women of
normal versus low BMD, and these are involved in several metabolic pathways such as sphingolipid
metabolism, phospholipid metabolism, and fatty acid β-oxidation. Moreover, this study demonstrates
that lipidomic and polar metabolic profiling are promising tools for finding novel biomarkers for bone
loss in SC women. Further, prospective studies on larger populations are needed to corroborate these
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findings and elucidate their key roles in osteoporosis development and progression in SC menopausal
women. Thus, understanding the cellular responses to molecular changes in bone metabolism and
how these are associated with bone loss in menopausal women may offer the potential of discovering
new biomarkers for prognosis of bone loss in elderly women.
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ACN Acetonitrile
BMD Bone mineral density
BMI Body mass index
BMUs Basic multicellular units
CTx-1 c-terminal telopeptide of type I collagen
DG Diacylglycerol
DXA Dual X-ray absorptiometry
EDTA Ethylenediamine tetraacetic acid





M-CSF Macrophage colony-stimulating factor
MSCs Mesenchymal stem cells






PPARy Peroxisome proliferator-activated receptor
PS Phosphatidylserine
PTH parathyroid hormone
ROS Reactive oxygen species
RP (LC-MS) Reverse-phase liquid chromatography mass spectrometry
SC Singaporean-Chinese
TNF-α Tumor necrosis factor-α
QC Quality control
WHO World Health Organization
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